Joanne B. Weidhaas, MD, PhD, MBM

Data from a study shared at the 2025 ASCO Annual Meeting showed that a microRNA-based model was able to predict irAEs in various cancers for those on anti-PD1 therapy.

Identifying which patients are at risk of distant failure may assist oncologists in deciding who should receive neoadjuvant radiation, according to Joanne B. Weidhaas, MD, PhD, MBM.

Joanne B. Weidhaas, MD, PhD, MBM, presented 2 abstracts based on microRNA technology at the 2025 ASCO Annual Meeting that demonstrated predictive power.